Last10K.com

Abbott Laboratories (ABT) SEC Filing 10-K Annual report for the fiscal year ending Wednesday, December 31, 2014

Abbott Laboratories

CIK: 1800 Ticker: ABT

Exhibit 99.1

 

 

 

 

 

 

 

 

 

 

 

Abbott Contacts:

 

Financial:

Brian Yoor

(224) 667-6343

 

Tina Ventura

(224) 668-7606

 

Scott Leinenweber

(224) 668-0791

 

Media:

Scott Stoffel

(224) 668-5201

 

Abbott Reports Fourth-Quarter 2014 Results

 

           Fourth-Quarter EPS Above Previous Guidance Range, Including Results From Discontinued Operations 

 

           Fourth-Quarter Operational Sales Growth of 10.2 Percent, Including Double-Digit Growth in Emerging Markets

 

           Significant Expansion of Full-Year Adjusted Operating Margin From Continuing Operations

 

           Issues Earnings Outlook for 2015 For Continuing Operations, Reflecting Top-Tier Growth at the Mid-Point 

 

ABBOTT PARK, III., Jan. 29, 2015 — Abbott today announced financial results for the fourth quarter ended Dec. 31, 2014.

 

·                  Diluted EPS, excluding specified items, was $0.71 in the fourth quarter and $2.28 for the full year, above Abbott’s previous guidance range and reflecting 13.4 percent growth. This includes results from both continuing and discontinued operations. Reported diluted EPS under GAAP was $0.59 in the fourth quarter and $1.49 for the full year. See page 2 for additional detail regarding financial results from discontinued operations.

 

·                  Fourth-quarter worldwide sales of $5.4 billion from continuing operations increased 10.2 percent on an operational basis, including double-digit growth in emerging markets. Worldwide sales increased 5.6 percent on a reported basis, including an unfavorable 4.6 percent effect of foreign exchange.

 

·                  For full-year 2014, Abbott expanded its adjusted operating margin ratio from continuing operations by 200 basis points over the prior year, primarily driven by continued improvements in Diagnostics, Nutrition and Vascular. The operating margin ratio from continuing operations under GAAP improved by 190 basis points over prior year.

 

·                  Abbott issues full-year 2015 EPS guidance for continuing operations, excluding specified items, of $2.10 to $2.20. Projected full-year 2015 EPS for continuing operations under GAAP is $1.33 to $1.43.

 

·                  In December, Abbott completed its acquisitions of Topera, Inc., a medical device company focused on developing innovative electrophysiology technologies, and Veropharm, a leading Russian pharmaceutical company.

 

·                  In Diagnostics, Abbott received European approval for its IRIDICA infectious disease testing platform and U.S. FDA clearance for a heart failure test on its ARCHITECT platform. In Medical Devices in the U.S., Abbott received FDA approval for its TECNIS® Multifocal Low Add intraocular lens (IOL) and launched its new XIENCE Alpinedrug-eluting stent system, designed for complex interventions.

 

“We ended 2014 with good momentum, well positioned for a step-up in operational sales growth in 2015,” said Miles D. White, chairman and chief executive officer, Abbott. “While we’ll need to manage through currency headwinds again in 2015, we’re targeting another year of top-tier earnings growth.”

 

 

- more -

 


The following information was filed by Abbott Laboratories (ABT) on Thursday, January 29, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Abbott Laboratories's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Abbott Laboratories.

Continue

Assess how Abbott Laboratories's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Abbott Laboratories's Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheet
Consolidated Balance Sheet (parenthetical)
Consolidated Statement Of Cash Flows
Consolidated Statement Of Comprehensive Income
Consolidated Statement Of Comprehensive Income (parenthetical)
Consolidated Statement Of Earnings
Consolidated Statement Of Shareholders' Investment
Consolidated Statement Of Shareholders' Investment (parenthetical)
Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (details)
Accumulated Other Comprehensive Income (tables)
Business Acquisitions
Business Acquisitions (details)
Business Acquisitions (tables)
Debt And Lines Of Credit
Debt And Lines Of Credit (details)
Debt And Lines Of Credit (tables)
Discontinued Operations
Discontinued Operations (details 2)
Discontinued Operations (details)
Discontinued Operations (tables)
Financial Instruments, Derivatives And Fair Value Measures
Financial Instruments, Derivatives And Fair Value Measures (details 2)
Financial Instruments, Derivatives And Fair Value Measures (details 3)
Financial Instruments, Derivatives And Fair Value Measures (details 4)
Financial Instruments, Derivatives And Fair Value Measures (details)
Financial Instruments, Derivatives And Fair Value Measures (tables)
Goodwill And Intangible Assets
Goodwill And Intangible Assets (details 2)
Goodwill And Intangible Assets (details)
Incentive Stock Program
Incentive Stock Program (details)
Incentive Stock Program (tables)
Litigation And Environmental Matters
Litigation And Environmental Matters (details)
Post-employment Benefits
Post-employment Benefits (details 2)
Post-employment Benefits (details 3)
Post-employment Benefits (details)
Post-employment Benefits (tables)
Quarterly Results (unaudited)
Quarterly Results (unaudited) (details)
Quarterly Results (unaudited) (tables)
Restructuring Plans
Restructuring Plans (details 2)
Restructuring Plans (details)
Restructuring Plans (tables)
Schedule Ii Valuation And Qualifying Accounts
Schedule Ii Valuation And Qualifying Accounts (details)
Segment And Geograhic Area Information (details)
Segment And Geographic Area Information
Segment And Geographic Area Information (details 2)
Segment And Geographic Area Information (details 3)
Segment And Geographic Area Information (tables)
Separation Of Abbvie Inc.
Separation Of Abbvie Inc. (details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details 2)
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Supplemental Financial Information
Supplemental Financial Information (details)
Supplemental Financial Information (tables)
Taxes On Earnings From Continuing Operations
Taxes On Earnings From Continuing Operations (details 2)
Taxes On Earnings From Continuing Operations (details)
Taxes On Earnings From Continuing Operations (tables)
Ticker: ABT
CIK: 1800
Form Type: 10-K Annual Report
Accession Number: 0001047469-15-001377
Submitted to the SEC: Fri Feb 27 2015 12:57:49 PM EST
Accepted by the SEC: Fri Feb 27 2015
Period: Wednesday, December 31, 2014
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/abt/0001047469-15-001377.htm